Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.

Saved in:
Bibliographic Details
Title: Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.
Authors: Fournier J; Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, France. jfournier@chu-grenoble.fr., Boussat B; Department of Epidemiology and Medical Evaluation, CHU Grenoble Alpes, Grenoble, and Laboratory TIMC, UMR 5525, CNRS, Joseph Fourier University, Grenoble, France., Dervaux B; Department of Research and Innovation, CHRU Lille, Lille, France., Gaudin P; T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France., Romand X; T-RAIG, TIMC, UMR 5525 CNRS, University of Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France.
Source: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2025 Jan; Vol. 43 (1), pp. 62-69. Date of Electronic Publication: 2024 Oct 03.
Publication Type: Journal Article
Journal Info: Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:0392-856X
DOI:10.55563/clinexprheumatol/3f60yv